- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01753531
Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B
June 20, 2013 updated by: Sekisui Diagnostics, LLC
A Multicenter Performance Evaluation for the Ultra Influenza A&B Test Using Nasal Swabs
The clinical performance of the Ultra Influenza A&B Test will be demonstrated during a clinical trial in which prospectively collected nasal swabs are used in identifying subjects who are infected with the influenza virus strain type A or type B. The Ultra Influenza A&B Test qualitative results will be compared to "Gold Standard" viral culture with Direct Fluorescent Antibody (DFA) confirmation techniques using nasal swabs collected from symptomatic subjects.
The Ultra Influenza A&B Test will be performed at Clinical Laboratory Improvement Amendments (CLIA) waived sites by untrained intended users (e.g.
nurses, physician assistants, medical assistants, etc.).
For viral culture testing with DFA confirmation testing, nasal swab specimen testing will be performed by a designated reference laboratory.
Study Overview
Study Type
Observational
Enrollment (Actual)
677
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- Ardmore Family Practice
-
-
South Carolina
-
Charleston, South Carolina, United States, 29412
- Pharmacorp Clinical Trials, Inc.
-
-
Texas
-
New Braunfels, Texas, United States, 78130
- Hill Country Medical Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects presenting with symptoms suggestive of influenza virus infection will be enrolled from geographically diverse CLIA Waived Intended Users (Physicians office laboratories, clinics or equivalents)
Description
Inclusion Criteria:
- The subject may be of any age and either gender.
- Preliminary assessment of the subject by the Investigator/designee should be suggestive of influenza virus infection. Subject should present with an influenza-like febrile respiratory illness defined as (1) presentation within the last 48 hours of developing a subjective feeling of being feverish and/or a temperature recorded at the clinic within the last 48 hours of greater than or equal to 100.5 F and (2) at least two of the following symptoms: cough, nasal congestion, rhinorrhea, sore throat, headache, myalgia.
Written informed consent must be obtained prior to study enrollment.
- A subject who is 18 years or older must be willing to give written informed consent and must agree to comply with study procedures.
- The legal authorized representative of a subject who is under the age of 18 must give written informed consent and agree to comply with study procedures. Active written assent should be obtained from children of appropriate intellectual age (as defined by the IRB).
Exclusion Criteria:
- The subject underwent a nasal wash/aspirate as part of standard-of-care testing during this study visit.
- The subject is undergoing treatment currently and/or within the past 7 days of the study visit with a nasally administered influenza vaccine (FluMist) or with anti-viral medication, which may include but is not limited to Amantadine (Symmetrel), Rimantadine (Flumadine), Zanamivir (Relenza), Oseltamivir (Tamiflu) or Ribavirin.
- The subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug or device, including either treatment or therapy.
- The subject has previously participated in this research study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Flu Symptoms
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify subjects who are infected with the virus strain type A or type B
Time Frame: 6 months
|
Characterize the performance of the Ultra Influenza A&B Test and to identify subjects who are infected with the influenza virus strain type A or type B. Performance data generated will support a 510k submission to FDA for clearance of the assay.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate the ability of untrained intended users to effectively run and read the Ultra Influenza A&B Test with insignificant risk of erroneous results.
Time Frame: 6 months
|
Demonstrate the ability of untrained intended users to effectively run and read the Ultra Influenza A&B Test with insignificant risk of erroneous results.
Qualitative results obtained using the Ultra Influenza A&B Test will be compared to viral culture with direct fluorescent antibody (DFA) confirmation testing on specimens collected during this study.
Data demonstrating ease of use will support a request to FDA for CLIA waived categorization of the assay.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert D Rosen, MD, Ardmore Family Practice
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (ACTUAL)
April 1, 2013
Study Completion (ACTUAL)
June 1, 2013
Study Registration Dates
First Submitted
December 17, 2012
First Submitted That Met QC Criteria
December 19, 2012
First Posted (ESTIMATE)
December 20, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
June 24, 2013
Last Update Submitted That Met QC Criteria
June 20, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAP-199
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza, Human
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
AVIR Green Hills Biotechnology AGCompletedSeasonal Human InfluenzaAustria
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Research Institute for Biological Safety ProblemsResearch Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...Completed
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Emergent BioSolutionsCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
-
Novartis VaccinesCompleted
Clinical Trials on Flu Symptoms
-
Sekisui Diagnostics, LLCBeaufort CROUnknown
-
GlaxoSmithKlineRecruiting
-
PepTcell LimitedCompleted
-
EDAN Instruments Inc.MDx CRO (MED IVD HEALTHTECH S.L.)RecruitingSARS-CoV2 Infection | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza BSpain
-
Groupe Hospitalier Paris Saint JosephCompleted
-
University of Southern CaliforniaWithdrawnImmunosenescence
-
University of California, San FranciscoAmerican Cancer Society, Inc.; Kaiser PermanenteCompleted
-
University of California, San FranciscoCenters for Disease Control and Prevention; San Francisco Department of Public...CompletedColorectal CancerUnited States
-
GlaxoSmithKlineCompleted
-
Ellume Pty LtdCompletedInfluenza A | Influenza BAustralia